LONDON, UK, 5th December 2007, Curidium Medica plc, (LSE:CUR), a personalized medicine company focused on bringing the right drug to the right patient, announced today that it has entered into a strategic partnership with Takeda Research Investment, Inc. (TRI), the corporate investment arm of Takeda Pharmaceutical Company, Limited. As part of the agreement TRI will purchase 10,491,803 ordinary shares and warrants for 20 million additional ordinary shares in the Company.
